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The main goal of the present paper was to examine the inﬂuence of the replacement of γ-Glu moiety to α-Glu in glutathione and
in its antioxidative tetrapeptidic analogue UPF1 (Tyr(Me)-γ-Glu-Cys-Gly), resulting in α-GSH and UPF17 (Tyr(Me)-Glu-Cys-
Gly), on the antioxidative defense system in K562 cells. UPF1 and GSH increased while UPF17 and α-GSH decreased the activity
of CuZnSOD in K562 cells, at peptide concentration of 10μM by 42% and 38% or 35% and 24%, respectively. After three-hour
incubation, UPF1 increased and UPF17 decreased the intracellular level of total GSH. Additionally, it was shown that UPF1 is not
degraded by γ-glutamyltranspeptidase, which performs glutathione breakdown. These results indicate that eﬀective antioxidative
c h a r a c t e ro fp e p t i d e sd o e sn o td e p e n do n l yo nt h er e a c t i v i t yo ft h ethiol group, but also of the other functional groups, and on the
spatial structure of peptides.
1.Introduction
Glutathione (GSH) system is an attractive target for drug
discovery because of its importance and versatility [1]. GSH
(γ-L-Glu-L-Cys-Gly) is a prevalent low molecular weight
thiol in eukaryotic cells and has antioxidative, detoxiﬁcative,
and regulatory roles [2, 3]. Decrease of GSH level and shifted
GSH redox status are related to several pathological states,
including neurodegenerative, cardiovascular, pulmonary,
and immune system diseases [4]. Exogenous administration
of GSH to compensate the decrease of GSH levels is not
reasonable because of its degradation in the plasma and
poor cellular uptake [5–7]. GSH and its oxidized disulﬁde
form (GSSG) are degraded by γ-glutamyltranspeptidase
(GGT) via cleavage of the amino acid γ-glutamate from
the N-terminal end of the peptide. GGT is located in the
outer side of the cell membrane, and one of its functions,
in cooperation with dipeptidases, is to provide cells with
precursor amino acids needed for GSH de novo synthesis.
To overcome the problems with GSH administration, several
GSH analogues have been created to increase the GSH
level and support the functionality of the GSH system [8].
We have previously designed and synthesized a library of
peptidic GSH analogues [9]. For this study, two of them,
UPF1 (Tyr(Me)-γ-Glu-Cys-Gly) and UPF17 (Tyr(Me)-Glu-
Cys-Gly), were selected. Both molecules have an O-methyl-
L-tyrosine residue added to the N-terminus of GSH-like
Glu-Cys-Gly sequence to increase the antioxidativity and
hydrophobicity. Previously, diﬀerent groups have shown
that various low molecular weight antioxidants, including
melatonin, carvedilol, and its metabolite SB 211475, carry
a methoxy moiety in their aromatic structures [10, 11].
The only structural diﬀerence between the peptides used
is that UPF17 contains α-glutamyl moiety while UPF1 has
γ-glutamyl moiety similarly to GSH. This switch from γ-
to α-glutamyl moiety improved hydroxyl radical scavenging
ability of UPF17 by approximately 500-fold compared to
UPF1 whereas UPF1 itself is about 60-fold better hydroxyl
radical scavenger than GSH [9]. In addition to being an
excellent invitro free radical scavenger,UPF1has shownpro-
tective properties against oxidative damage in a global brain
ischemia/reperfusion model and in an ischemia/reperfusion2 International Journal of Peptides
model on an isolated heart of Wistar rats [12, 13]. UPF1 and
UPF17 have been shown to be nontoxic for K562 cells up to
concentration of 200μM and UPF1 has no toxic eﬀect on the
primary culture of cerebellar granule cells at concentrations
up to 100μM[ 9, 13].
Superoxide dismutases (SOD, EC 1.15.1.1.) are metal-
loproteins and the primary enzymes that keep cellular free
radical production under control [14]. Cytosolic CuZnSOD
is a homodimer (151 amino acids) with a molecular weight
of 32500Da and contains two cysteines (Cys57, Cys148)
bound into an intramolecular disulﬁde bond and two free
cysteines (Cys6, Cys111) [15, 16]. SOD catalyses the dismu-
tation of superoxide into oxygen and hydrogen peroxide.
Hydrogen peroxide as a diﬀusible cell damaging agent is fur-
ther eliminated by glutathione peroxidase or catalase. One of
the essential requirements for the biological activity of the
glutathione peroxidase is glutathione as a cosubstrate. Con-
sequently, SOD works synergistically with the glutathione
against free radical damage.
This study examined the inﬂuence of UPF1 and UPF17
on CuZnSOD activity and intracellular GSH level in K562
cells.Theaimofstudyingthesetetrapeptideswastogetinfor-
mation about whether and how the replacement of γ-pep-
tide bond with α-peptide bond in the structure aﬀects the
bioactivities of the peptides. Additionally, we measured the
stability of the peptides towards GGT to clarify their status in
biologicalsystems and the pKa values for thiol group disso-
ciation.
2.MaterialsandMethods
2.1. Peptide Synthesis. UPF peptides were synthesized man-
ually by solid phase peptide synthesis using Fmoc-chemistry
and by machine using tert-Boc-chemistry as described pre-
viously[9, 17]. The purity of the peptides was >99% as dem-
onstrated by HPLC on an analytical Nucleosil 120-3 C18 re-
versed-phasecolumn(0.4cm×10cm)andthepeptideswere
identiﬁed by MALDI-TOF (matrix-assisted laser desorption
ionization time-of-ﬂight) mass-spectrometry (Voyager DE
Pro, Applied Biosystems).
2.2.CuZnSODActivityinK562Cells. TheK562cells(human
erythroleukemiacells,obtainedfromDSMZ,Germany)were
grown in T75 cell culture ﬂasks in RPMI 1640 supplemented
with 2mM glutamine (PAA, Austria), 7.5% fetal calf serum,
streptomycin (100μg/mL), and penicillin (100U/mL) (all
from Invitrogen, USA) at 37◦C in a humidiﬁed 5% carbon
dioxide atmosphere. Cells were seeded at concentration of
1.0 × 106 per mL. Experiments were conducted 24h after
passage. Peptides (GSH, α-GSH, UPF1 and UPF17) diluted
in DPBS (PAA, Austria) were added to the ﬂasks containing
the K562 cells. The cells were incubated with DPBS as
control (Co) or with the peptide solution in a concentra-
tion range from 0.5 to 10μMf o r2 4ha t3 7 ◦C. The peptide
concentrations were chosen based on the GSH concen-
tration in the blood plasma. After treatment, the cells were
washed twice with DPBS and then lysed in water by keep-
ing on ice for 20min. Samples were centrifuged (12000g)
for 10min and supernatants were transferred for experi-
ments. The protein concentrations in the supernatants were
d e t e r m i n e db yL o w r y ’ sm e t h o d[ 18]. CuZnSOD activity
was measured with the commercially available kit (Randox
Laboratories Ltd, UK). This method employs xanthine and
xanthine oxidase to generatesuperoxide radicals, which react
with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-phe nyltetrazol-
ium chloride to form a red formazan dye. The superoxide
dismutase activity is then measured by the degree of
inhibition of this reaction. One unit of SOD inhibited 50%
of the rate of reaction.
2.3.MeasurementofTotalGlutathione. Concentrationsofto-
tal glutathione (tGSH) were assessed by an enzymatic meth-
od of Tietze [19] .T h eh o m o g e n a t ew a sd e p r o t e i n a t e db y
10% solution of metaphosphoric acid (Sigma-Aldrich, Ger-
many) in water and centrifuged at 12000g for 10min. The
enzymatic reaction was initiated by the addition of NADPH,
glutathione reductase, and 5,5 -dithio-bis-2-nitrobenzoic
acid in buﬀer containing EDTA (Sigma-Aldrich, Germany).
The change in optical density was measured after 15min at
412nmspectrophotometrically(SunriseTecan).Glutathione
content was calculated on the basis of a standard curve.
2.4. Stability towards γ-Glutamyltranspeptidase. 1mMUPF1
was incubated with 0.3mg/mL equine kidney γ-glutamyl-
transpeptidase in 0.1M Tris-HCl buﬀer pH 7.4, supple-
mented with 0.1% EDTA (Sigma-Aldrich, Germany) at 37◦C
for 1h. 6mM Gly-Gly was added as an acceptor for γ-Glu
moiety [20]. GSH was incubated with GGT under the same
conditions as the control. The samples were heat-inactivat-
ed, centrifuged at 10000g and +4◦C for 5min, and kept on
ice until analyzed. Supernatants were analyzed on a Promi-
nence HPLC (Shimadzu, Japan) and Q-Trap 3200 (Applied
Biosystems, USA) mass spectrometry tandem. Luna C18 100
× 2mm, 3μm column from Phenomenex was used for sam-
ple separation. Solvent A was a mixture of 99.9% water
and 0.1% HCOOH, and solvent B was a mixture of 99.9%
acetonitrile and 0.1% HCOOH (mass spectrometry grade,
Riedel-de Ha˙ en, Germany). Samples were eluated at a ﬂow
rate of 0.1mL/min, gradient started with 5min at isocratic
ﬂow of solvent A, concentration of solvent B increased up
to 30% in 25min, followed by wash with 100% solvent B
in 20min. Enhanced MS scans were performed in negative
mode with rate 1000amu/s between mass range 50–1700Da.
Ionsprayvoltagewassetto −4500V,declusteringpotentialto
−30V and entrance potential to −10V.
2.5. pKa of Thiol Groups. The ratio of thiol and thiolate
concentrations were measured spectrophotometrically at
240nm on a PerkinElmer Lambda 25 spectrometer similarly
as previously for GSH and α-GSH [21]. 1mL of 50μM
peptide solution in phosphate buﬀered saline (Calbiochem,
USA) was titrated with 5μL volumes of 1M NaOH and
pH and absorbance changes were determined after each ad-
dition. The results were corrected to consider the dilution of
the assay mixture during titration.International Journal of Peptides 3
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Figure 1: Modulation of CuZnSOD activity by GSH and UPF1 in
K562 cells. The CuZnSOD activity of Co is 100%. ∗P<0.05; ∗∗P<
0.01, GSH and UPF1 versus Co; n = 4–8.
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Figure 2: Modulation of CuZnSOD activity by GSH and α-GSH
(10μM) in K562 cells. The CuZnSOD activity of Co is 100%. ∗P<
0.05; ∗∗P<0.01, 10μMG S Ho rα-GSH versus Co; n = 4–8.
2.6. Statistical Analysis. Data were analyzed using GraphPad
Prism version 4.00 for Windows (GraphPad Software, San
Diego, CA, USA). The results on the graphs are presented
as the mean ± standard error of the mean (SEM).
3. Results
3.1. CuZnSOD Activity. K562 cells were incubated with
investigated peptides (GSH, α-GSH, UPF1, and UPF17) for
24hatfourdiﬀerentconcentrations:0.5,1.0,5.0,and10μM.
GSH showed a concentration-dependent activating eﬀect
on CuZnSOD activity, whereas 10μM GSH increased the
enzyme activity by 38% (Figure 1). α-GSH had an inhibiting
eﬀect (24%) on the enzyme activity but only at the highest
concentration used (10μM) (Figure 2). UPF1 increased the
activity of CuZnSOD at concentrations of 1.0, 5.0, and
10μM, but at concentration of 0.5μM showed an inhibition
of the enzyme activity (Figure 1). The activation rate was
concentration dependent. Contrary to UPF1, UPF17 showed
an inhibitory eﬀect and the inhibition was not concentration
dependent.UPF1increasedandUPF17decreasedtheactivity
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Figure 3: Modulation of CuZnSOD activity by UPF1 and UPF17
(10μM) in K562 cells. The CuZnSOD activity of Co is 100%. ∗P<
0.05; ∗∗P<0.01, 10μM UPF1 or UPF17 versus Co; n = 4–8.
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Figure 4: Alteration of tGSH concentration by UPF1 and UPF17
in K562 cells. The tGSH concentration of Co is 100%. ∗P<0.05,
∗∗∗P<0.005, UPF1 or UPF17 versus Co; n = 6–8.
of CuZnSOD at peptide concentration of 10μM by 42% and
35%, respectively (Figure 3). As the peptide concentration of
10μM was the most eﬀective, it selected for the comparison.
3.2. Intracellular GSH Level. K562 cells were incubated with
UPF1 and UPF17 peptides for 3h at concentrations of
0.05, 0.10, and 0.5mM. Previous experiments have shown
that at these concentrations UPF peptides are eﬀective free
radicalscavengersandarebiologicallyactive.Inaddition, the
0.5mM concentration was chosen to match with millimolar
GSH concentration in number of cells. UPF1 increased and
UPF17 decreased GSH concentration at concentrations of
0.05 and 0.1mM by 29% and 26% or 26% and 28%, respec-
tively (Figure 4). No statistical diﬀerence in tGSH concen-
tration compared to control after incubation with 0.5mM
peptides, the highest concentration used, was detected.
3.3. Degradation by GGT. After incubating GSH with GGT,
GSH was degraded and γ-Glu moiety was transferred to an
acceptor Gly-Gly dipeptide, resulting in a new compound in4 International Journal of Peptides
mass spectra with MW 261.2Da [γ-Glu-Gly-Gly]. The ques-
tionarose:canthebondbetweenγ-glutamateandcysteinebe
degraded by GGT in UPF1, where the access to the bond is
obstructed by an additional amino acid methylated tyrosine?
Results obtained from the mass spectrometry measurements
demonstrated that UPF1 is not degraded by GGT as the
expected peaks with or without acceptor dipeptide MW
438.4Da [Tyr(Me)-γ-Glu-Gly-Gly] or 324.3Da [Tyr(Me)-γ-
Glu], respectively, did not appear. During the incubation,
UPF1 was dimerised over disulphide bridge. GGT is also
able to breakdown dimeric form of GSH, but degradation of
dimerised UPF1 was not detected.
3.4. pKa. The pKa values of thiol groups of the peptides were
measured.ForGSHandα-GSH,thevalueswere9.0±0.3and
9.1 ± 0.1, respectively, whereas pKa values for UPF peptides
were slightly higher: 9.3 ± 0.1f o rU P F 1a n d9 .4 ± 0.2f o r
UPF17.
4. Discussion
The present study focused on the eﬀects of UPF1 and UPF17
on CuZnSOD activity and intracellular GSH level in K562
cells. For the ﬁrst time we described and compared counter-
point biological activities of structural antioxidative peptide
analogs diﬀering from each other by spacial arrangement
of Glu residue (γ-peptide bond in UPF1 changed to the α-
peptide bond in UPF17). Previously we have shown that
UPF1 and UPF17 have a tendency for MnSOD activation.
However, the γ-glutamyl moiety containing UPF1 needed
more time for MnSOD activation compared to UPF17,
which had the eﬀect already after 5min incubation. UPF1
and UPF17 have also diﬀerent inﬂuence on glutathione
peroxidaseactivity(GPx):athigherconcentrationsthanused
in in vivo experiments, both UPF1 and UPF17 inhibited
activity concentration dependently whereas the α-peptide
bond containing UPF17 had stronger inhibitory eﬀect [22].
In the present work we investigated how the replacement
of γ-peptide bond with α-peptide bond on GSH and its
analogueUPF1aﬀectsCuZnSODactivityandlevelofGSHin
K562 cells. The results showed that γ-Glu moiety containing
GSH and UPF1 stimulated CuZnSOD activity and increased
intracellular tGSH level, whereas α-GSH and UPF17, which
have α-Glu moiety in the structure, inhibited enzymatic
activity and decreased GSH level. The stability of UPF1
towards GGT activity indicated that UPF1 aﬀects GSH level
and CuZnSOD activity as intact molecule instead of being
a GSH precursor. Previously, it has been shown that GSH
and UPF1 are able to act as signaling molecules through G-
p r o t e i na c t i v a t i o ni nf r o n t o c o r t i c a lm e m b r a n ep r e p a r a t i o n s
[23]. It has been reported that plasma membranes have
speciﬁc binding sites of GSH which have an interaction
with the glutamate binding sites [24]. By this way GSH and
UPF peptides may aﬀect the metabolism of cells as signal
molecules. The eﬀects on the level of GSH and CuZnSOD
activity may be diﬀerent depending on the replacement of γ-
peptide bond with α-peptide bond. GSH has been shown to
bind to ionotropic glutamate receptors via gamma-glutamyl
residue in the nervous tissue [25]. Additionally, glutamate
receptors have been found also in the plasma membrane of
megakaryocytes and rat erythrocytes [26, 27]. By interacting
with the latter receptors, GSH and UPF peptides may aﬀect
the metabolism of cells as signal molecules through the PKC
pathway and aﬀect CuZnSOD activity. The various eﬀects of
thestudiedmoleculesmaybecausedbystructuraldiﬀerences
between the GSH and UPF peptides (replacement of γ-
peptide bond with α-peptide bond).
UPF1 and UPF17 have also shown diﬀerent eﬀects
in free radical scavenging experiments. According to the
classiﬁcation of kinetic behavior by S´ anches-Moreno et al.,
UPF17 is classiﬁed as fast and UPF1 as intermediate DPPH
radical scavenger [9, 28]. In silica modeling of noncovalent
complex formation by docking calculations revealed a more
aﬃne complex between DPPH radical and α-GSH compared
to the complex with GSH [21]. This raised a question about
pKa values for the thiol groups of UPF peptides. Previously,
the change of γ-peptide bond to α-peptide bond has also
been investigated for GSH and its α-analogue: pKa of thiol
groups were similar for GSH and α-GSH (9.0 ± 0.1a n d
9.1 ±0.1) [21]. The comparison of these results with current
measurements for UPF1 and UPF17 demonstrated that pKa
value is rather inﬂuenced by the addition of a methylated
tyrosine moiety to the GSH backbone than by the change
of the peptide bond type. Smaller pKa values for GSH
and its α-analogue showed that these molecules donate the
sulfhydryl proton more easily than UPF peptides; however,
UPF peptides are better radical scavengers. This indicates
that reactive species elimination does not depend only of the
reactivity of the thiol group.
The results of the current paper show that γ-peptide
bond and α-peptide bond containing UPF peptides may
inﬂuence enzyme activities in diﬀerent direction, which
oﬀers a wider perspective for the usage of glutathione ana-
logues as protective diverse regulators of the oxidative state.
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